News

Rating 0 - Votos (0)

191 visitas

publicado el 13/03/2022

Mambisa waits for the authorization for emergency use.

Once the reports about the clinical trial Baconao are ready, the Centro de Ingeniería Genética y Biotecnología (CIGB) will ask for the authorization of the emergency use of the vaccinal candidate against COVID-19 Mambisa.

The authorization for the emergency use of the vaccinal candidate against COVID-19 Mambisa will be asked by the  Centro de Ingeniería Genética y Biotecnología (CIGB), once the reports about the clinical trial Baconao are ready.    

 According to the official profile of CIGB in Twitter, Baconao research, studies the effect of this inmunogenous as a reinforcement dose.

It was approved in November 2021 by the Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos, Baconao  is a  phase II clinical trial, developed in the province of Matanzas which  evaluates the effect and safety  of a reinforcement dose with Mambisa or the vaccine Abdala against COVID-19, in individuals previously vaccinated with Abdala.

A report of Granma newspaper specifies that it is a multi-centric and random trial, in which 1500 and 3 000 workers of tourism and health sectors took part, as populations at risk with more than five months of having the last dose. Half of the subjects had Abdala, and the other half had Mambisa.

According to the media, the clinical study is on the evaluation and processing of data « When the reports are ready, the authorization for emergency use will be asked for and that will make Mambisa, a vaccine », CIGB explained in Twitter.

Mambisa is one of the nasal vaccinal candidate against COVID-19 –CIGB added – with more advance investigations in the world, and the first to start clinical research in humans. 

Mambisa is developed by CIGB, is based on protein antigens and produced with safe and efficient technology, used for more than 30 years, it does not need Tiomersal for its production, that is an advantage for the allergic people to this compound.

Related Information

The vaccine Abdala file is expected to be presented to the WHO in March.

https://lahabana.gob.cu/post_detalles/es/13171/preven-entregar-en-marzo-expediente-de-la-vacuna-abdala-a-la-oms

 

Your opinion matters
Leave your comments

When you make your comment, note that

  • You must not use offensive words.
  • It must be in relation to the topic.
  • It must published comply with the above policies to be published.




0 comments inserted